March 10, 2021
March 10, 2021 – The U.S. FDA has approved AVEO Pharmaceuticals’ Fotivda® (tivozanib) to treat relapsed
or refractory advanced renal cell carcinoma (RCC) in adults who have had two or
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
March 9, 2021
March 9, 2021 – Bryant Ranch Prepack has issued a voluntary recall of 47 bottles of Spironolactone tablets in 25mg and 50mg dosage strengths. The recalled product may be mislabeled
March 8, 2021
March 8, 2021 – Genentech has voluntarily withdrawn an indication for Tecentriq® (atezolizumab) to treat
metastatic urothelial carcinoma (mUC) in patients who have previously received
March 8, 2021
March 8, 2021 – The U.S. FDA has granted tentative approval for a generic version of AstraZeneca’s Symbicort® (budesonide/formoterol fumarate dihydrate) inhalation aerosol. The generic
March 5, 2021
March 5, 2021 – The U.S. FDA has approved an expanded indication for Flucelvax® Quadrivalent (influenza
vaccine), manufactured by Seqirus. The vaccine is indicated to provide active immunization
March 5, 2021
March 5, 2021 – The U.S. FDA has approved a new indication for Yescarta® (axicabtagene ciloleucel),
manufactured by Gilead, to treat relapsed or refractory follicular lymphoma (FL)
March 4, 2021
March 4, 2021 – The U.S. FDA has approved a new indication for Actemra® (tocilizumab), manufactured
by Roche, to slow the rate of pulmonary function decline in adults who have systemic
March 3, 2021
March 3, 2021 - Important Updates Regarding Additional Populations Eligible to Receive COVID-19 Vaccines and Authorization for Johnson & Johnson's Janssen Biotech, Inc. COVID-19 Vaccine